Mylan NV (MYL) Pops 2.67% for February 22

Equities Staff  |

One of the S&P 500’s big winners for Monday February 22 was Mylan NV (MYL) as the company’s stock climbed 2.67% to $46.55 on volume of 3.7 million shares.

The stock opened at $46.35 and saw an intraday low of $45.63 and an intraday high of $46.64. All told, the day saw a per-share gain of $1.21. The stock’s average daily volume of 7.81 million and 490.69 million shares outstanding. Mylan NV now has a 50-day SMA is $51.25 and 200-day SMA is $55.45, and it has a 52-week high of $76.69 and a 52-week low of $37.59.

Mylan NV along with its subsidiaries is a pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Based out of Hatfield, , Mylan NV has 35,000 employees and, after today’s trading, reached a market cap of $22.84 billion. The stock’s P/E Ratio is 27.3. Its P/S ratio is 2.36, P/B ratio is 2.34, and P/FCF ratio is 23.4.

For a complete fundamental analysis analysis of Mylan NV, check out’s Stock Valuation Analysis report for MYL. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Crypto World in Review: Taking in the Good with the Bad

A lot happened in the cryptocurrency industry this week.

Emerging Growth

Lexaria Bioscience Corp

Lexaria Bioscience Corp is a food sciences company. It has two distinct consumer product brands: ViPova and Lexaria Energy. It uses patent pending technology to infuse hemp oil ingredients within…